pharma
Boehringer Ingelheim Vetmedica
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica patent portfolio — 21 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2018
- Programs
- 0
- Drugs
- 0
- Patents
- 21
Boehringer Ingelheim Vetmedica patents
21 pharmaceutical patents indexed for Boehringer Ingelheim Vetmedica. 0 expire within 24 months.
Boehringer Ingelheim Vetmedica has 21 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
MX 2025012909
METHOD FOR INDUCING AN IMMUNE RESPONSE
granted -
WO 2025210141
SYSTÈME D'ADMINISTRATION UTILE POUR L'ADMINISTRATION TOPIQUE D'ARN
granted -
US 2025281584
ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS
granted -
AR 132581
COMPOSICIÓN INMUNÓGENA ÚTIL PARA LA AUTOADMINISTRACIÓN POR CERDOS
granted -
US 2025195525
ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS
granted -
WO 2025046414
VECTEURS DE CDV VIA ET LEURS UTILISATIONS
granted -
WO 2025046413
VECTEURS DE VIA DE VMN ET LEURS UTILISATIONS
granted -
US 2025064917
HVT AIV VECTORS AND USES THEREOF
granted -
WO 2025027551
VACCIN ANTI-IBV AVEC PROTÉINE DE SPICULE DE DMV/1639 HÉTÉROLOGUE
granted -
US 2024390332
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more SGLT-2 inhibitors and telmisartan
granted -
US 2024390317
COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN
granted -
WO 2024223388
COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS
granted -
PT 3721882
TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS
granted -
US 2024307628
SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S)
granted -
UY 40647
DERIVADOS DE ETILSULFONA/SULFOXIMINA-PIRIDINA SUSTITUIDOS CON TETRAZOL
granted -
UY 40646
DERIVADOS DE N-ÓXIDO DE ETIL-SULFONA/SULFOXIMINA-PIRIDINA SUSTITUIDOS CON CICLOPROPIL-(HETERO)ARILO
granted -
UY 40645
DERIVADOS DE ETIL-SULFOXIMA-PIRIDINA SUSTITUIDOS CON CICLOPROPIL-(HETERO)ARILO
granted -
US 2024197727
SOLID DISPERSIONS COMPRISING AMORPHOUS PIMOBENDAN AND ONE OR MORE STABILIZING POLYMERS
granted -
WO 2024033462
CELLULES SOUCHES MÉSENCHYMATEUSES À UTILISER DANS LE TRAITEMENT DE L'HYPERSENSIBILITÉ AUX PIQÛRES D'INSECTES CHEZ DES ÉQUIDÉS
granted -
US 2023381101
AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS
granted -
CA 3255048
COMPOSITION IMMUNOGÈNE UTILE POUR LA VACCINATION CONTRE LES ROTAVIRUS
granted
Frequently asked questions
How many patents does Boehringer Ingelheim Vetmedica have?
21 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Boehringer Ingelheim Vetmedica patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.